Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: • Summarize the current state of the science regarding pathogenic mechanisms of chronic GVHD and critical knowledge gaps. • Develop working hypotheses/overriding concepts for chronic GVHD development. • Define the usefulness of curr...
Graft-versus-host disease (GVHD) is a disabling complication after allogeneic hematopoietic stem cel...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Hematopoietic cell transplantation (HCT) is frequently complicated by graft-versus-host disease (GVH...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
AbstractClinical research into chronic graft-versus-host disease (GVHD) lags behind that in other ar...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
Chronic graft-versus-host disease (cGVHD), a multiorgan disorder, is the leading cause of late nonre...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
Graft-versus-host disease (GVHD) is a disabling complication after allogeneic hematopoietic stem cel...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Hematopoietic cell transplantation (HCT) is frequently complicated by graft-versus-host disease (GVH...
AbstractChronic graft-versus-host disease (GVHD) remains a vexing and dangerous complication of allo...
AbstractClinical research into chronic graft-versus-host disease (GVHD) lags behind that in other ar...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
Chronic graft-versus-host disease (cGVHD), a multiorgan disorder, is the leading cause of late nonre...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractChronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic hemato...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
Graft-versus-host disease (GVHD) is a disabling complication after allogeneic hematopoietic stem cel...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...